What a Notice of Compliance means in Health Canada reviews
A Notice of Compliance is Health Canada's authorization after a satisfactory new drug review. How NDS, ANDS and SNDS lead to one, and how to check it.
What Health Canada's Notice of Compliance means
A Notice of Compliance (NOC) is issued by Health Canada after satisfactory review of a submission for a new drug. It signifies compliance with the Food and Drug Regulations (Health Canada). A submission under review has not necessarily received an NOC. Check the NOC database rather than inferring approval from a review list (submissions under review).
What a Notice of Compliance means
The legal weight comes from section C.08.002 of the Food and Drug Regulations. A new drug may not be sold or advertised unless the listed conditions are met. Those include a satisfactory submission, an NOC issued under C.08.004 or C.08.004.01, and an NOC that has not been suspended under C.08.006 (C.08.002). The NOC is a key authorization requirement, not a certificate that every other legal obligation for a launch has been met.
Under C.08.004, an NOC is issued after examination when the submission or supplement complies with the applicable requirements. When it does not, the outcome is a notice of noncompliance, a different document from a Notice of Compliance.
An older NOC alone does not show that authorization remains unsuspended (C.08.002). Certain significant changes require a supplement and an unsuspended NOC under C.08.003. A minor change does not automatically need a new submission.
How NDS, ANDS and SNDS lead to an NOC
All three submission types can end in an NOC. C.08.004 expressly covers a new drug submission, an abbreviated new drug submission and a supplement (C.08.004).
| Submission | What it is | Legal basis |
|---|---|---|
| NDS (new drug submission) | Gives enough information for the Minister to assess a new drug's safety and effectiveness, including manufacturing and quality information, detailed safety reports and substantial evidence of clinical effectiveness for the recommended purpose and conditions of use | C.08.002 |
| ANDS (abbreviated new drug submission) | The generic route, built on comparison with a Canadian reference product: pharmaceutical equivalence, bioequivalence, the same route of administration and conditions of use within those of the reference product | C.08.002.1 |
| SNDS (supplemental new drug submission) | Covers specified significant changes to an already authorized new drug, such as manufacturing methods and controls, specifications, labels, dosage, claims, contraindications, route of administration or dosage form | C.08.003 |
An NDS is not limited to new active substances (C.08.002). The abbreviated route still needs enough information to assess safety and effectiveness (C.08.002.1). A supplement can add a new indication, and it also covers other specified significant changes (C.08.003).
Submissions under review are not approvals
Health Canada publishes the Submissions Under Review (SUR) lists to show what is in the queue. A submission is added after it is accepted into review, and it stays on the list through interim negative decisions and administrative or regulatory holds. There are four lists, each updated monthly: new drug submissions under review, supplemental submissions under review, new drug submissions completed, and supplemental submissions completed (Health Canada, SUR).
- The SUR lists cover NDSs for new active substances and NDSs and supplemental NDSs for new uses. The supplemental list does not cover every SNDS or post-approval change (SUR).
- "Completed" does not mean "approved". A submission moves to a completed list when it is cancelled or when a final decision is made. Health Canada points readers to the NOC database to see whether a submission was approved (SUR).
- Generics have their own Generic Submissions Under Review (GSUR) list. It covers ANDSs accepted into review from October 1, 2018. It is also updated monthly, keeps entries through interim negative decisions and holds, and removes them when they are cancelled or finally decided. Removal from GSUR is not evidence of approval (Health Canada, GSUR).
The SUR and GSUR pages are monthly snapshots. Treat them as a picture of the review queue at their stated "current to" date, not a live feed (SUR, GSUR).
How to search for a Notice of Compliance
Use the Notice of Compliance database search for the authorization record. Health Canada states the database is updated nightly and holds NOCs for human drugs from January 1, 1994 to date (NOC database). Look for the product and the submission you care about. Note the NOC date.
For the reasons behind a decision, two other Health Canada documents help:
- The submissions under review overview points to Regulatory Decision Summaries for positive and negative decisions and cancellations, with a more detailed Summary Basis of Decision where one applies (SUR).
- Summary Basis of Decision (SBD) documents explain why Health Canada authorized certain drugs for sale, including regulatory, safety, effectiveness and quality considerations. For drugs, the overview's Phase II coverage is NDSs for new active substances and biosimilars (Health Canada, SBD).
Not every submission gets an SBD, and an SBD reflects the decision at the time rather than up-to-date product information (SBD FAQ). A missing SBD is therefore not proof that a drug lacks an NOC. Keep the authorization record separate from the explanation of the decision.
You can see how RegAffairs AI answers what a Notice of Compliance is, with citations to the official Health Canada sources.